MyoVista® high sensitivity ECG (hsECG™) device is an innovative advancement in low cost electrocardiographic testing. Electro-cardiography, initially developed in the late 19th century, has been an indispensable front-line tool to assist the physician in evaluating patients for heart disease. With the introduction of the MyoVista hsECG device, HeartSciences brings breakthrough innovation to electrocardiography that adds new capabilities to assist in early testing for the detection of cardiac dysfunction.
MyoVista benefits from more than 10 years of research and development focused on improving ECG technology. MyoVista hsECG device produces a sensitivity of 78% and a specificity of 71%* for the detection of diastolic dysfunction. During a recent clinical trial MyoVista technology produced a sensitivity of 88% and a specificity of 87%* using machine learning analysis which indicates even greater future capability for the detection of diastolic dysfunction.
• Data on file at HeartSciences